Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: A pilot study

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 245, Issue 5, 2007, Pages 651-655

  Abrahám Marin, Maura Lucy ^a,c   Cortés Luna, Carlos Fernando ^b   Álvarez Rivera, Griselda ^a,c   Hernández Rojas, Myriam ^a   Quiroz Mercado, Hugo ^a   Morales Cantón, Virgilio ^a  

^a HOSPITAL DR LUIS SÁNCHEZ BULNES   (Mexico)

^b Clínica de Ojos   (Colombia)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Angiogenesis inhibitors; Antibodies; Choroidal neovascularisation; Macular degeneration

Indexed keywords

BEVACIZUMAB;

AGED; ANTERIOR EYE CHAMBER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE INFLAMMATION; EYE INJURY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; IMAGE ANALYSIS; LENS DISEASE; MALE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PILOT STUDY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA THICKNESS; SINGLE DRUG DOSE; SLIT LAMP; SUBRETINAL NEOVASCULARIZATION; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION; VISUAL SYSTEM PARAMETERS;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 34250769632     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-006-0411-6     Document Type: Article

References (21)

1. Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111-118
2. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805-2816
3. Gryziewicz L (2005) Regulatory aspects of drug approval for macular degeneration. Adv Drug Deliv Rev 57:2092-2098
4. Holekamp NM, Bouck N, Volpert O (2002) Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularisation due to age-related macular degeneration. Am J Ophthalmol 134:220-227
5. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F (2005) Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508
6. Macular Photocoagulation Study Group (1991) Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 109:1109-1114
7. Michels S, Rosenfeld PJ (2005) Therapie der neovaskulären altersbedingten Makuladegeneration mit Ranibizumab/Lucentis. Klin Monatsbl Augenheilkd 222:480-484
8. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035-1047
9. Miller DW, Joussen AM, Holz FG (2003) Die molekularen Mechanismen der neovaskulären AMD. Ophthalmologe 100:92-96
10. Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM, Birngruber R, van den Berg H, Strong A, Manjuris U, Gray T, Fsadni M, Bressler NM, Gragoudas ES (1999) Photodynamic therapy with verteporfin for choroidal neovascularisation caused by age-related macular degeneration: Results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 117:1161-1173
11. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V et al (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27:536-544
12. Ng EW, Adamis AP (2005) Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 40:352-368
13. Otani A, Takagi H, Oh H, Koyama S, Matsumura M, Honda Y (1999) Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci 40:1912-1920
14. Pauleikhoff D (2005) Neovascular age-related macular degeneration: Natural history and treatment outcomes. Retina 25:1065-1084
15. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331-335
16. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N (2005) Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112:1048-1053
17. Schlingemann RO (2004) Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 242:91-101
18. Shah MA, Ilson D, Kelsen DP (2005) Thromboembolic events in gastric cancer: High incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 23:2574-2576
19. Ta CN (2004) Minimizing the risk of endophthalmitis following intravitreous injections. Retina 24:699-705
20. Waheed NK, Miller JW (2004) Aptamers, intramers, and vascular endothelial growth factor. Int Ophthalmol Clin 44:11-22
21. Witmera AN, Vrensenb GF, Van Noorden CJF, Schlingemann RO (2003) Vascular endothelial growth factors and angiogenesis in eye diseases. Prog Retin Eye Res 22:1-29